Company / Return on Equity (ROE)
CRISPR Therapeutics AG Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-30.3%
FY2025
5-year range
-34.7% / 15.7%
FY2021-FY2025
Trend
-59.6%
vs FY2024
Sector context
#101 of 190
Health Care
What the data says
CRISPR Therapeutics AG reports negative total equity of -30.3% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-30.3% in FY2025 with a 5-year CAGR of -9.3%.
Declined from -8.2% to -30.3% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +4.4pp
- 5-Year Change
- -9.3pp
- 10-Year Change
- -
Sector benchmark
#101 of 190 in Health CareTop 53% of 190This company -30.3% Sector average -50.3%
▼
+39.8% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 59.6% year-over-year.
- Currently 20.0pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -30.3% | -59.6% |
| FY2024 | -19.0% | -132.4% |
| FY2023 | -8.2% | +76.5% |
| FY2022 | -34.7% | -320.3% |
| FY2021 | 15.7% | +175.1% |
| FY2020 | -21.0% | -394.4% |
| FY2019 | 7.1% | +116.9% |
| FY2018 | -42.1% | -15.6% |
| FY2017 | -36.4% | -265.7% |
| FY2016 | -10.0% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026